secwatch.observer — SEC 8-K summary
======================================

Issuer:     GYRE THERAPEUTICS, INC. (GYRE)
CIK:        0001124105
Form:       8-K
Filed at:   2023-10-30T23:59:59+00:00
Accession:  0001140361-23-050292
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.95
Item codes: 1.01, 2.01, 3.02, 3.03, 5.03, 5.01, 5.02, 5.05, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Catalyst completes reverse merger with Beijing Continent, renames to Gyre Therapeutics
--------------------------------------------------------------------------------

- GNI USA acquired ~85.3% ownership; old Catalyst stockholders hold ~2.5%; minority holders ~12.3%.
- Reverse stock split 1-for-15; authorized shares increased to 400M; ticker changes to GYRE from CBIO.
- Private placement of $5.0M via convertible preferred stock and warrants to GNI USA.
- New board appointed; Charles Wu named CEO, Songjiang Ma President, Ruoyu Chen Interim CFO.
- Business focus shifts to organ fibrosis drug development from Beijing Continent Pharmaceuticals.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1124105/000114036123050292/0001140361-23-050292-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1124105/000114036123050292/ny20009756x10_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-23-050292

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer